Systemic treatments for metastatic cutaneous melanoma.

摘要: Background Systemic therapies for metastatic cutaneous melanoma, the most aggressive of all skin cancers, remain disappointing. Few lasting remissions are achieved and therapeutic aim remains one palliation. Many agents used alone or in combination with varying degrees toxicity cost. It is unclear whether evidence exists to support these complex regimens over best supportive care / placebo. Objectives To review benefits from use systemic melanoma compared care/placebo, establish a 'standard' therapy which superior other treatments. Search methods Randomised controlled trials were identified MEDLINE, EMBASE CCTR/CENTRAL databases. References, conference proceedings, Science Citation Index/Scisearch also locate trials. Cancer registries trialists contacted. Selection criteria Randomised adults histologically proven anti-cancer was placebo care. Data collection analysis Study selection performed by two independent reviewers. Data extraction forms studies appeared meet criteria and, where appropriate, full text articles retrieved reviewed independently. Main results No randomised found comparing melanoma. Authors' conclusions There no clinical show superiority treatment malignant melanoma. Given that patients frequently receive therapy, it our pragmatic view future systematic could compare any treatment, treatments, single agent dacarbazine.